Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFIC	IAL OWNERSHIP
---------------------------------	---------------

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Aggarwal Sumit				2. Issuer Name and Ticker or Trading Symbol Eloxx Pharmaceuticals, Inc. [ELOX]					(Che	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last)	,	First) RMACEUTICAI	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/24/2024					2	below)	(give title ESIDENT A	Other (s below)	pecify		
480 ARSENAL WAY, SUITE 130					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) WATERT	TOWN I	MA	02472										led by One Repled by More that	•		
(City)	(State)	(Zip)	Ī	Rule	10b5-	1(c)	Transac	tion Ind	ication						
					Check this box to indicate that a transaction was made pursuant to a contract, instruction or satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						n or written plan	that is intended	to			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date			2. Transacti Date (Month/Day	Execution Date		Date,	Code (Instr. 5)				es Form ally (D) of Following (I) (Ir	n: Direct or Indirect Bristr. 4)	7. Nature of Indirect Beneficial Ownership			
							Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)		Instr. 4)		
		-	Fable II - D					uired, Dis , options,				Owned				
Derivative Conversion Date			Execution Date		Code (Instr.		of I		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Cod	e V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Restricted Stock Units	(1)	01/24/2024		A		60,000		(2)	(2)	Common Stock	60,000	\$0.00	60,000	D		

Explanation of Responses:

- 1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- 2. The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date.

/s/ Sumit Aggarwal

01/26/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.